Collaborative Medicinal Development
During 20 years of practice as a board-certified hematologist and oncologist, devised, conducted, and led numerous clinical research protocols from preclinical research to FDA approval, resulting in close to 100 publications in peer-reviewed journals and book publications. Craig Rosenfeld was a Chief Scientific Officer and Senior Vice President of SuperGen, Inc. (2002-2004), responsible for directing the pivotal clinical trials leading to FDA approval of Dacogen and Director of Bone Marrow Transplant programs at the Western Pennsylvania Cancer Institute (1990-1994) and Medical City Dallas Hospital (1994-2001).
This person is not in any offices
Collaborative Medicinal Development
Collaborative Medicinal Development is a clinical stage company developing novel disease modifying drugs for the treatment of both neurodegenerative diseases and cancer. They are building a portfolio by both inventing new chemical entities in house and licensing promising leads from third parties.